FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Hard to Treat Diseases Inc. Stock AnalysisComprehensive stock analysis for Hard to Treat Diseases Inc. (HTDS) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisHTDS
HTDS
Hard to Treat Diseases Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
HTDS
Home🔹Stocks🔹Hard to Treat Diseases Inc.

Hard to Treat Diseases Inc.

HTDS•OTC

Hard to Treat Diseases Inc.

HTDS•OTC
Market cap
$109.65K
Sentiment

Your view on HTDS

Mkt Cap
$109.65K
Sentiment
Your view
HTDS
Hard to Treat Diseases Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
HTDS
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Hard to Treat Diseases Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Shimin Yuan
Headquarters
Room EF, 12F, Shenzhen, CN
Industry
Biotechnology
Sector
Healthcare
CEO
Shimin Yuan
Headquarters
Room EF, 12F, Shenzhen, CN
Description

Hard to Treat Diseases Inc. manufactures, supplies, and exports biopharmaceuticals and vaccines in China and internationally. The company offers biologicals, including reteplase (rPA), mycobacterium vaccae, acutobin urinary kallidinogenase, ulinastatin, and cerebroprotein hydrolysate for injection; chemicals, such as cobratide injection, entecavir capsule, HES, dasatinib tablets, thymosin a1 for injection, imipenem and cilastatin sodium for injection, and meropenem for injection; and vaccines, which include rabies vaccine, ACYW135 meningococcal vaccine, influenza vaccine, Hepatitis A, and varicella vaccine. It markets its products through a sales network that focuses on South Asia, South-east Asia, Central and South America, and the Middle East. Hard to Treat Diseases Inc. was founded in 2009 and is based in Shenzhen, China.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News